Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. Our platform approach integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity.
Recludix is employing this platform approach first in the development of SH2 domain inhibitors for the treatment of inflammatory disease and cancer. SH2 domains have been recognized as playing a key role in disease signaling pathways for over 30 years; however, scientists had been unable to target them for the development of therapeutics. Recludix has developed a novel SH2-focused platform that integrates new chemical approaches and technologies, including custom SH2 domain libraries and assays, to develop precision small molecule medicines.
The company’s most advanced programs are focused on Signal Transducer and Activator of Transcription (STAT) proteins found within the Janus Kinase (JAK)/STAT signaling pathway. Abnormal STAT activation is found in numerous inflammatory diseases, such as rheumatoid arthritis, asthma, atopic dermatitis, inflammatory bowel disease, as well as many cancer types, such as multiple leukemias and lymphomas. Recludix has a portfolio of STAT inhibitors and other programs with undisclosed targets, including one that leverages its domain-agnostic platform towards a high-value, non SH2-domain target. Recludix’s lead wholly-owned development program is an oral STAT3 inhibitor.
Additionally, Recludix has a global strategic partnership with Sanofi to advance an oral STAT6 inhibitor in multiple immunology and inflammation indications. Recludix has an option to participate in an equal profit-sharing arrangement in the U.S., which includes certain co-promotion activities.